Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Interaction between ELAVL1 and M6A Regulators in Prostate Cancer
21 Pages Posted: 14 Mar 2022
More...Abstract
Prostate cancer (PCa) is a common tumor in elderly men. N6-methyladenosine (m6A) imbalance is an important factor in the occurrence and development of PCa. Many m6A regulators have been found to be significantly dysregulated in PCa. ELAVL1 is an m6A binding protein that is highly expressed in various tumors and can promote the occurrence and development of tumors in an m6A-dependent manner. In this study, we found that most m6A regulators were significantly dysregulated in PCa, and some m6A regulators were associated with the progression-free interval. Mutations and copy number variations of these m6A regulators can alter their expression. However, ELAVL1 mutations were not found in PCa. Nevertheless, ELAVL1 upregulation was closely related to PCa proliferation. High ELAVL1 expression was also related to RNA metabolism. Further experiments showed that ELAVL1 interacted with other m6A regulators and that several m6A regulatory mRNAs have m6A sites that can be recognized by ELAVL1. Additionally, protein–protein interactions occur between ELAVL1 and other m6A regulators. Finally, we found that the dysregulation of ELAVL1 expression occurred in almost all tumors, and interactions between ELAVL1 and other m6A regulators also existed in almost all tumors. In summary, ELAVL1 is an important molecule in the development of PCa, and its interactions with other m6A regulators may play important roles in PCa progression.
Funding: This work is supported by the grant from National Natural Science Foundation
of China (Grant Nos. 81970656 and 62101319).
Declaration of Interest: All authors declare that they have no competing interests.
Ethical Approval: The studies involving human prostate cancer samples were reviewed
and approved by the Ethics Committee of Shanghai Outdo Biotech Company.
Keywords: prostate cancer, ELAVL1, m6A, m6A regulators, interaction
Suggested Citation: Suggested Citation